SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Ocata Therapeutics Inc. (OCAT)

Add OCAT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator elysse1kittycat, sports guy, LODE MAKING ME RICH, homeslice10, lasers, AyeEye
Search This Board:
Last Post: 7/31/2015 11:03:36 AM - Followers: 644 - Board type: Free - Posts Today: 10

 Ocata Therapeutics (OCAT)

formerly Advanced Cell Technology (ACTC):
Advanced Cell Technology Changes Name to Ocata Therapeutics

Ocata Therapeutics Headquarters
33 Locke Drive
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333 

Company Overview

Ocata Therapeutics, Inc. (“Ocata”; NASDAQ: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. 

Regenerative Ophthalmology Platform

The mission behind our Regenerative Ophthalmology efforts is clear. It is our goal to bring innovative new therapies to the market to treat diseases of the eye that otherwise may cause significant loss of vision in patients. Our emerging cell therapies focus on structural repair and functional restoration and have the potential to make a significant difference in the lives of people with ocular disorders.

We are at the forefront of developing new therapies to address some of the most significant unmet medical needs in eye diseases. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigmentosa, as well as inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.

  • Our lead clinical program involves RPE Cell Therapy for treating macular degeneration. Critical to the development and the rate of progression of macular degeneration is the health status of the retinal pigment epithelium, or RPE, a single layer of cells whose presence and integrity in the retina are required for normal vision. The company is currently conducting clinical trials in the U.S. andU.K. for treating Stargardt’s macular degeneration with the RPE Cell Therapy, and in the U.S. for treating patients with dry age-related macular degeneration.
    We are developing a Photoreceptor Progenitor Cell Therapy which we intend to be used for treating a wide variety of retinal degenerations in diseases where photoreceptors malfunction and/or die.
    Our Ganglion Progenitor Cell Therapy is a preclinical candidate program. In animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells as well as forms new ganglion nerve cells.
    The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness.

See our Pipeline of Ophthalmology Therapies »

Other Regenerative Medicine Programs

In addition to our regenerative ophthalmology programs we have invested in other programs where we feel that we can leverage our expertise in cellular and developmental biology to generate allogeneic therapies that have the potential to improve health care in other prevalent degenerative diseases and diseases of aging. At the core of our pipeline planning are approaches intended to address large unmet medical needs with allogeneic stem cell-derived therapeutics.

Our Mesenchymal Stem Cells

Our Mesenchymal Stem Cells (MSCs) represent an “off-the-shelf” cellular therapy ready for treatment of autoimmune and inflammatory diseases in both acute and chronic settings. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component, which makes them an attractive tool for the cellular treatment of autoimmunity and inflammation. We believe we have succeeded at creating a differentiated MSC product by producing the cells in culture from a pluripotent stem cell source.

Neuroprotective Biologics

We have discovered Neuroprotective Biologics that are secreted by certain of our neurosensory retina progenitor cell populations. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson’s Disease, and ischemic events such as caused by stroke.

Blood Components Programs

Through our Blood Components Programs, we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other cells relevant immune response or hemostasis.


Pipeline of Therapeutic Programs

Ocata’s world-class research and development programs embody our efforts to bring transformative new therapies to market for patients facing some of hardest-to-treat eye diseases and disorders.




Press Releases






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.




Rules of the board according to IHUB:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
News News Alert: Ocata Therapeutics to Host Conference Call and Webcast to Provide Corporate Update for the Second Quarter of 2015 07/31/2015 08:00:00 AM
#86201  Sticky Note Transcript: Paul Wotton, Cantor Fitzgerald Inaugural Healthcare Conference, 7/8/ runcaly 07/09/15 03:30:22 PM
#76767  Sticky Note Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation lasers 11/24/14 12:12:44 PM
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#86908   OCAT: at least the 2k shares I bought north40000 07/31/15 11:03:36 AM
#86907   Wow at this writing the stock is actually elysse1kittycat 07/31/15 10:42:50 AM
#86906   fulleroots, I think the current stock price is miserable. elllk 07/31/15 10:41:10 AM
#86905   Whats your evaluation of this miserable stock price fulleroots 07/31/15 09:52:51 AM
#86903   Captain Kirk, what is your evaluation of the elllk 07/31/15 09:05:49 AM
#86902   I am not disagreeing with you but imo elysse1kittycat 07/31/15 08:59:36 AM
#86901   Suggest a look at the compensation of 2013 AyeEye 07/31/15 08:28:16 AM
#86900   Ocata Therapeutics to Host Conference Call and Webcast manfromjax 07/31/15 08:07:58 AM
#86899   Wow-your last statement is certainly disturbing at best. elysse1kittycat 07/31/15 12:30:44 AM
#86898   I wonder what Lanza thinks about all the 2020 07/30/15 11:57:01 PM
#86897   Wow X Wow, i bet he is kissing fulleroots 07/30/15 11:38:05 PM
#86896   Another right on target post, imo. farviewhill 07/30/15 10:11:28 PM
#86895   Sorry to say that I sadly felt the farviewhill 07/30/15 10:08:05 PM
#86894   Good point. farviewhill 07/30/15 08:50:27 PM
#86893   True..I shouldn't give them any ideas, i know fulleroots 07/30/15 05:28:56 PM
#86892   How about the promise to have a jv elysse1kittycat 07/30/15 05:01:33 PM
#86891   Video SAID PHASE II STARTING in 2 WEEKS, Captain Kirk 07/30/15 04:38:23 PM
#86890   Executives of a company - get options....they almost DFRAI 07/30/15 04:19:56 PM
#86888 Reetala 07/30/15 03:45:55 PM
#86887   I agree with you. elysse1kittycat 07/30/15 03:44:43 PM
#86884   I get it, but like i said..If it fulleroots 07/30/15 03:30:20 PM
#86883   Its the Ocata version of "Why buy the elysse1kittycat 07/30/15 03:24:52 PM
#86882   This is why the RS was done at fulleroots 07/30/15 03:13:18 PM
#86879   You deserve that a lot more than the elysse1kittycat 07/30/15 12:36:32 PM
#86878   I didn't get a Christmas card or an AyeEye 07/30/15 12:28:26 PM
#86877   For self-serving reasons known only to the head elysse1kittycat 07/30/15 12:26:45 PM
#86875   Its too bad that there isn't something akin elysse1kittycat 07/30/15 11:52:14 AM
#86874   OR, how he says they're a $230 MILLION Captain Kirk 07/30/15 11:47:38 AM
#86872   How come no mention of how the talks elysse1kittycat 07/30/15 11:22:18 AM
#86871   RED, and DAY'S LOW at $4.10 ???????????????? Captain Kirk 07/30/15 11:22:01 AM
#86870   Lmao this guy sure does refer to his fulleroots 07/30/15 11:21:56 AM
#86869   It's hard to believe that PW can watch Shiskabill 07/30/15 11:16:34 AM
#86868   No commercial products until 2019 was something prior AyeEye 07/30/15 11:09:48 AM
#86867   You are actually making my point. elysse1kittycat 07/30/15 11:02:20 AM
#86866   Do you believe that shareholders are rewarded when AyeEye 07/30/15 10:49:09 AM
#86865   Yet another day when the stock price is elysse1kittycat 07/30/15 10:26:06 AM
#86863   Captain Kirk, what is your opinion of Lanza’s elllk 07/30/15 09:47:29 AM
#86861   The rise and fall and rebirth of Ocata. King215grill 07/30/15 01:42:34 AM
#86860   I am confused. elysse1kittycat 07/30/15 01:25:37 AM
#86859   PW signed up: all we need is investors King215grill 07/30/15 01:19:27 AM
#86858   OCAT quote: "The company has published unprecedented trial elysse1kittycat 07/30/15 12:52:04 AM
#86857   Snap back coming in PPS... read this and ruREDe 07/30/15 12:25:03 AM
#86856   OCAT quote: "The company has published unprecedented trial chuckanutman 07/29/15 11:53:36 PM
#86855   Paul Wotton as the CEO of Ocata so elysse1kittycat 07/29/15 11:31:40 PM
#86854   AyeEye, it's easy to see the analogy in chuckanutman 07/29/15 11:11:20 PM
#86853   There is nothing like seeing your wallet become elysse1kittycat 07/29/15 10:17:52 PM
#86852   To bad that video has nothing to do fulleroots 07/29/15 10:13:31 PM
#86851   Thanks Chuck! AyeEye 07/29/15 10:00:35 PM
#86850   Nothing like getting your eyesight back or seeing chuckanutman 07/29/15 08:45:44 PM
#86849   Still Holding.... but losing my faith tzarkee 07/29/15 06:08:48 PM